- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.06. | AB&B BIO-TECH-B (02627): QUARTERLY UPDATE ON RESUMPTION PROGRESS; POSTPONEMENT OF THE 2025 ANNUAL GENERAL MEETING; AND CONTINUED SUSPENSION OF TRADING | - | HKEx | ||
| 23.06. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY CHINA CDE FOR MRNA MPOX VACCINE | 1 | HKEx | ||
| AB&B BIO-TECH Aktie jetzt für 0€ handeln | |||||
| 05.06. | AB&B BIO-TECH-B (02627): APPOINTMENT OF INDEPENDENT INVESTIGATOR AND INDEPENDENT INTERNAL CONTROL CONSULTANT | 1 | HKEx | ||
| 27.05. | AB&B BIO-TECH-B (02627): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 27.05. | AB&B BIO-TECH-B (02627): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 27.05. | AB&B BIO-TECH-B (02627): (1) POLL RESULTS OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 (2) ABOLITION OF THE SUPERVISORY COMMITTEE, AMENDMENTS TO ... | - | HKEx | ||
| 13.05. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - COMMENCEMENT OF PHASE I AND PHASE II CLINICAL TRIALS FOR RECOMBINANT RSV VACCINE (CHO CELL) (ADJUVANT) | 1 | HKEx | ||
| 08.05. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY CHINA CDE FOR MRNA RSV VACCINE | 1 | HKEx | ||
| 08.05. | AB&B BIO-TECH-B (02627): FORM OF PROXY FOR THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 TO BE HELD ON WEDNESDAY, MAY 27, 2026 AND ANY ADJOURNMENT THEREOF | 2 | HKEx | ||
| 08.05. | AB&B BIO-TECH-B (02627): (1) ABOLITION OF THE SUPERVISORY COMMITTEE (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION (3) AMENDMENTS TO CERTAIN INTERNAL CORPORATE ... | 1 | HKEx | ||
| 07.05. | AB&B BIO-TECH-B (02627): NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 | - | HKEx | ||
| 29.04. | AB&B BIO-TECH-B (02627): RESUMPTION GUIDANCE AND CONTINUED SUSPENSION OF TRADING | - | HKEx | ||
| 24.04. | AB&B BIO-TECH-B (02627): (I) NOMINATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR (II) CHANGE OF BOARD COMMITTEE MEMBERS AND (III) PROPOSED AMENDMENTS TO ... | - | HKEx | ||
| 24.04. | AB&B BIO-TECH-B (02627): PROPOSED APPOINTMENT OF AUDITOR | 3 | HKEx | ||
| 14.04. | AB&B BIO-TECH-B (02627): PROPOSED CHANGE OF AUDITOR | 1 | HKEx | ||
| 01.04. | AB&B BIO-TECH-B (02627): INSIDE INFORMATION: (1) DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025; (2) POSTPONEMENT ... | 1 | HKEx | ||
| 19.03. | AB&B BIO-TECH-B (02627): DATE OF BOARD MEETING | 1 | HKEx | ||
| 13.03. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - ENTERING INTO OF STRATEGIC COOPERATION AGREEMENT | 1 | HKEx | ||
| 04.03. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY U.S. FDA FOR MRNA MPOX VACCINE | 1 | HKEx |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 88,30 | +0,11 % | Kurssprünge und Kaufempfehlungen! Neues Kursziel bei Almonty! CTS Eventim und BioNTech melden sich zurück! | Was für ein Comeback! Im August ist die Aktie von Almonty um über 50 % explodiert! Dafür gibt es gute Gründe. Wolfram ist im Westen knapp und wird von der hochfahrenden Waffenproduktion in den USA dringend... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Personalentscheidungen / Vorstand/Strategische Unternehmensentscheidung
QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now | ||
| HARMONY BIOSCIENCES | 39,210 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| ERASCA | 18,040 | +0,06 % | Erasca, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,97 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,670 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Merck, Vidac Pharma, Moderna - Neue Krebswaffen elektrisieren die Börse | Ein Durchbruch in der Krebsforschung versetzte die Börse in der vergangenen Woche in Euphorie. Eine personalisierte mRNA-Therapie hat erstmals in einer großen Phase-3-Studie entscheidende Ziele erreicht... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 345,01 | +0,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,760 | -0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,08 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,210 | +0,06 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,370 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,770 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen |
Das Unternehmen AB&B BIO-TECH CO LTD JS kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AB&B BIO-TECH CO LTD JS finden Sie auf Wallstreet Online.